Takeda to Establish Four Sales and Marketing Subsidiaries

Takeda Pharmaceutical Company LimitedTakeda Pharmaceutical Company Limited (Osaka, Japan, "Takeda") will establish four new commercial subsidiaries covering Mexico, Turkey, Sweden, Norway, Denmark, Belgium and Luxembourg. The new subsidiaries - Takeda Pharmaceuticals Mexico, S.A. de C.V., Takeda Pharmaceuticals Trade, LLP (Turkey), Takeda Pharmaceuticals Nordics AB (Sweden), and Takeda Pharmaceuticals Benelux SPRL (Belgium) - are part of Takeda's strategic global expansion efforts.

"Takeda has a significant opportunity to expand our presence in Mexico, Europe and other priority markets," said Alan MacKenzie, Executive Vice President (EVP) International Operations, Takeda Pharmaceuticals International, Inc. "Executing our territory expansion strategy is an important step toward further globalizing our operations and enhancing our ability to bring important medicines to patients who need them."

The Mexican pharmaceutical market is the 12th largest in the world and accounts for approximately 25 percent of the pharmaceutical sales throughout Latin America. The population in Mexico is increasing, and access to healthcare continues to grow, with the market increasing faster than in the United States and Europe, making it a key region for Takeda's expansion.

Nordics and Benelux are strategically important regions in Europe - Norway, Sweden, Denmark, Belgium and Luxembourg have a combined pharmaceutical market size which accounts for five percent of the European pharmaceutical market. Following the buy-back of Actos® (pioglitazone) in October 2008, Takeda will be distributing Actos in the five countries. The creation of these commercial subsidiaries will further increase Takeda's reach in the regions.

The Turkish pharmaceutical market is one of the largest global pharmaceutical markets, ranked sixth in Europe and 13th worldwide with the fastest forecasted growth rate in Europe over the next five years. Takeda also recently re-acquired the rights to Actos in this market, providing the business with a strong product with which to enter the market.

Overall, the new subsidiaries will accelerate Takeda's expansion efforts for core products including Actos and reinforces Takeda's global operating infrastructure. The company will work toward the earliest possible approval and launch of new products in these regions. Takeda's presence in these seven new countries builds upon other expansions announced in 2009 including commercial operations in Spain, Portugal, Ireland, and Canada.

About Takeda Pharmaceutical Company Limited
Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Takeda is enhancing its R&D pipeline by concentrating its management resources in the following selected core therapeutic areas: lifestyle-related diseases, oncology and urological diseases (including gynecology), central nervous system diseases (including bone and joint disorders), and gastroenterological diseases. For more information, please visit http://www.takeda.com.

Most Popular Now

Roche launches imCORE, a global network of cancer …

Roche (SIX: RO, ROG; OTCQX: RHHBY) has launched the global cancer immunotherapy Centers of Research Excellence (imCORE™) Network. This network brings together many of the...

Read more

15th Annual eyeforpharma Philadelphia 2017

20 - 21 April 2017, Philadelphia, USA. It's eyeforpharma Philadelphia's 15th year; already the largest, most senior and most influential forum for commercial pharma exec...

Read more

Merck wins R&D 100 Award for top invention

Merck, a leading science and technology company, received a prestigious R&D 100 Award for its Sanger Arrayed Lentiviral CRISPR Libraries - the first of its kind CRISPR li...

Read more

Benzodiazepine and related drug use increases hip …

The use of benzodiazepines and related drugs increases the risk of hip fracture by 43% in persons with Alzheimer's disease, according to a new study from the University o...

Read more

Among antidementia drugs, memantine is associated …

A recent study from the University of Eastern Finland shows that among users of antidementia drugs, persons using memantine have the highest risk of pneumonia. The use of...

Read more

World of viruses uncovered

A groundbreaking study of the virosphere of the most populous animals - those without backbones such as insects, spiders and worms and that live around our houses - has u...

Read more

Boehringer Ingelheim and China Southeast Universit…

Boehringer Ingelheim and China Southeast University Institute of Life Sciences have announced the start of a joint research project to develop new treatment approaches fo...

Read more

Smart patch releases blood thinners as needed

An interdisciplinary team of researchers has developed a smart patch designed to monitor a patient's blood and release blood-thinning drugs as needed to prevent the occur...

Read more

Novartis acquires Selexys Pharmaceuticals Corporat…

Novartis today announced it has acquired Selexys Pharmaceuticals Corporation, a company specializing in development of therapeutics in certain hematologic and inflammator...

Read more

Novo Nordisk expands programme to reach 20,000 chi…

Today, Novo Nordisk announced a four-year extension of its Changing Diabetes® in Children programme which provides access to diabetes care and free insulin to children wi...

Read more

IBM and Pfizer to accelerate immuno-oncology resea…

IBM (NYSE: IBM) Watson Health and Pfizer Inc. (NYSE: PFE) have announced a collaboration that will utilize IBM Watson for Drug Discovery to help accelerate Pfizer's resea...

Read more

Greater efforts are needed to encourage patients t…

In a review of published studies addressing patients' perceptions and factors influencing their reporting of adverse drug reactions, most patients were not aware of repor...

Read more

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]